A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06
Tekijät: Albertsen BK, Harila-Saari A, Jahnukainen K, Lahteenmaki P, Riikonen P, Mottonen M, Lausen B
Kustantaja: TAYLOR & FRANCIS LTD
Julkaisuvuosi: 2019
Journal: Leukemia and Lymphoma
Tietokannassa oleva lehden nimi: LEUKEMIA & LYMPHOMA
Lehden akronyymi: LEUKEMIA LYMPHOMA
Vuosikerta: 60
Numero: 6
Aloitussivu: 1469
Lopetussivu: 1475
Sivujen määrä: 7
ISSN: 1042-8194
eISSN: 1029-2403
DOI: https://doi.org/10.1080/10428194.2018.1538507
Tiivistelmä
Acute lymphoblastic leukemia (ALL) is a rare disease in infants. Asparaginase is an essential part of the treatment, and there Acute is a need to evaluate the efficiency and safety of this drug in this age group. We evaluated the pharmacokinetics of intramuscularly administered native E. coli asparaginase (Asparaginase Medac((R))) and PEG-asparaginase (Oncaspar((R))) as well as hypersensitivity reactions during treatment in Interfant-06 (www.clinicaltrials.gov: NCT01025804). All patients without hypersensitivity had sufficiently high enzyme activity levels during treatment with both preparations. Patients with hypersensitivity reactions during treatment, characterized by the presence of either or not of clinical symptoms and no measurable enzyme activity, received ineffective therapy. For optimization of the bad prognosis in infant ALL, therapeutic drug monitoring should be performed for identification of patients who should be switched to a different asparaginase preparation because of inactivation of the drug.
Acute lymphoblastic leukemia (ALL) is a rare disease in infants. Asparaginase is an essential part of the treatment, and there Acute is a need to evaluate the efficiency and safety of this drug in this age group. We evaluated the pharmacokinetics of intramuscularly administered native E. coli asparaginase (Asparaginase Medac((R))) and PEG-asparaginase (Oncaspar((R))) as well as hypersensitivity reactions during treatment in Interfant-06 (www.clinicaltrials.gov: NCT01025804). All patients without hypersensitivity had sufficiently high enzyme activity levels during treatment with both preparations. Patients with hypersensitivity reactions during treatment, characterized by the presence of either or not of clinical symptoms and no measurable enzyme activity, received ineffective therapy. For optimization of the bad prognosis in infant ALL, therapeutic drug monitoring should be performed for identification of patients who should be switched to a different asparaginase preparation because of inactivation of the drug.
Turun yliopiston Tutkimustietojärjestelmän portaali